New approaches in cancer treatment

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer chemotherapy; Drug development; Gene chips; Gene therapy; Monoclonal antibody therapy; Multidrug resistance

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BIRICODAR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLADRIBINE; DOCETAXEL; FENTANYL; FLUDARABINE PHOSPHATE; GEMCITABINE; GRANISETRON; IRINOTECAN; LY 335976; NAVELBINE; OC 144093; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PAMIDRONIC ACID; PENTOSTATIN; RALTITREXED; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESEARCH; HAIRY CELL LEUKEMIA; HUMAN; HYPERCALCEMIA; LUNG CANCER; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0033378651     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S149     Document Type: Conference Paper

References (53)

1. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-9.
2. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43 S61-8.
3. Saven A, Piro LD. 2-Chlorodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120: 784-91.
4. Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J Sci Am 1998; 4 Suppl 2: S27-36.
5. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6: 421-33.
6. Fidias P, Chabner BA, Grossbard ML. Purine analogs for the treatment of low-grade lymphoproliferative disorders. Oncologist 1996; 1: 125-139.
7. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85: 1261-8.
8. Dooley M, Goa KL. Capecitabine. Drugs 1999; 58: 69-76.
9. Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology 1999; 57 Suppl 1: 16-20.
10. Touroutoglou N, Pazdur R. Thymidylate synthase inhibitors. Clin Cancer Res 1996; 2: 227-43.
11. Brito RA, Medgyesy D, Zukowski TH et al. Fluoropyrimidines: A critical evaluation. Oncology 1999; 57 Suppl 1: 2-8.
12. Raymond E, Chancy SG, Taamma A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 10: 1053-71.
13. Di Leo A, Piccart MJ. Paclitaxel activity, dose, and schedule: Data from phase III trials in metastatic breast cancer; Semin Oncol 26 (3 Suppl 8): 27-32.
14. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999; 26 (3 Suppl 9): 32-6.
15. O'Leary J, Muggia FM. Camptothecins: A review of their development and schedules of administration. Eur J Cancer 1998; 34: 1500-8.
16. Abang AM. The clinical pharmacology of topoisomerase I inhibitors. Semin Hematol 1998; 35 (3 Suppl 4): 13-21.
17. Arbuck SG, Takimoto CH. An overview of topoisomerase I targeting agents. Semin Hematol 1998; 35 (3 Suppl 4): 3-12.
18. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998; 42: S31-43.
19. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-100.
20. Clark R, Ihde DC. Small-cell lung cancer: Treatment progress and prospects. Oncology 1998; 12: 647-58.
21. Johnston EM, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol. 1998; 25: 552-61.
22. Fauser AA, Fellhauer M, Hoffmann M, et al. Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer 1999; 35: 361-70.
23. Payne R. Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Oncology (Huntingt) 1998; 12: 169-75.
24. Desikan KR, Dhodapkar MV, Munshi NC, et al. Recent advances in the treatment of multiple myeloma. Curr Opin Hematol 1999; 6: 216-21.
25. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.
26. Gottesman M: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-754.
27. Fisher GA and Sikic BI: Clinical studies with modulators of multidrug resistance. In: Fisher GA and Sikic BI: Drug Resistance in Clinical Oncology and Hematology. Hematology Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995, 363-382.
28. Fisher GA, Lum BL, Hausdorff J, et al. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 1996; 32A:1082-1088.
29. Beketic-Oreskovic L, Duran GE, Chen, G et al.: Decreased mutation rate for doxorubicin resistance and suppression of mdr1 gene activation by PSC 833. J Natl Cancer Inst 1995; 87: 1593-1602.
30. Sparreboom A, van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-5.
31. van Asperen J, van Tellingen O, Sparreboom A et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-3.
32. van Asperen J, van Tellingen O, van der Valk MA et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreatcd with cyclosporin A. Clin Cancer Res 1998; 4: 2293-7.
33. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998; 352 (9124): 285.
34. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999; 26 (4 Suppl 12): 41-50.
35. Buske C, Feuring-Buske M, Unterhalt M et al. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy. Eur J Cancer 1999; 35: 549-57.
36. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88.
37. Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies. Oncology (Huntingt) 1998; 12 (10 Suppl 8): 63-76.
38. Shak S. Overview of the trastuzamab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999; 26 (4 Suppl 12): 71-7.
39. Goldenberg MM. Trastuzamab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-18.
40. Pluda JM. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-18.
41. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80 (Suppl 1): 57-64.
42. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17-38.
43. van Hinsbergh VW, Collen A, Koolwijk P. Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors. Ann Oncol 1999: 10 (Suppl 4): 60-3.
44. Fidler IJ. Critical determinants of cancer metastasis: Rationale for therapy. Cancer Chemother Pharmacol 1999; 43: S3-10.
45. Alvarez AA, Krigman HR, Whitaker RS et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999; 5: 587-91.
46. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta 1999; 1423: C19-30.
47. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
48. Heise CC, Williams AM, Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59: 2623-8.
49. Howard BD, Kalthoff H, Fong TC. Ablation of tumor cells in vivo by direct injection of HSV-thymidine kinase retroviral vector and ganciclovir therapy. Ann N Y Acad Sci 1999; 880: 352-65.
50. Hamstra DA, Rice DJ, Fahmy S, et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003.
51. Khan J, Saal LH, Bittner ML et al. Expression profiling in cancer using cDNA microarrays. Electrophoresis 1999; 20: 223-9.
52. Kurian KM, Watson CJ, Wyllie AH. DNA chip technology. J Pathol 1999; 187: 267-71.
53. Khan J, Bittner ML, Chen Y et al. DNA microarray technology: the anticipated impact on the study of human disease. Biochim Biophys Acta 1999; 1423(2): M17-28.